title: Entecavir Reduces Hepatocarcinogenesis in Chronic Hepatitis B Patients.
abstract: Chronic hepatitis B (CHB) leads to cirrhosis and hepatocellular carcinoma (HCC). With a cohort of 1,206 CHB patients who visited Okayama University Hospital and related hospitals in 2011 and 2012, we compared the incidence rates of HCC among the patients grouped by age, hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg), and treatment. HCCs were observed in 115 patients with the median observation period of 1,687 days. Among the HCC patients aged > 35 years, HBV DNA > 4 log copies/mL and positive HBeAg at diagnosis (n＝184), the HCC incidence rate was 8.4% at 5 years in the entecavir (ETV)-treated patients, 21.8% in the lamivudine (LVD)-treated patients, and 26.4% among the patients not treated with drugs. The cumulative HCC incidence was significantly reduced in the ETV-treated patients compared to those treated with LVD or not treated (p＝0.013). Among the patients aged >35 years with HBV DNA > 4 log copies/mL and negative HBeAg (n＝237), the cumulative HCC incidence was 14.6% in 5 years in ETV group and 13.9% among those not treated with a drug (p＞0.05). Only small numbers of HCCs occurred in other patients. In CHB patients aged > 35 years with HBV DNA > 4 log copies/mL and positive HBeAg, ETV treatment is recommended for the suppression of HCC development.
authors.affiliation: Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Yasunaka
authors.forename: Fusao
authors.initials: F
authors.lastname: Ikeda
authors.forename: Nozomu
authors.initials: N
authors.lastname: Wada
authors.forename: Yuki
authors.initials: Y
authors.lastname: Morimoto
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Fujioka
authors.forename: Junichi
authors.initials: J
authors.lastname: Toshimori
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Kobashi
authors.forename: Kazuya
authors.initials: K
authors.lastname: Kariyama
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Morimoto
authors.forename: Hiroki
authors.initials: H
authors.lastname: Takayama
authors.forename: Tomonori
authors.initials: T
authors.lastname: Seno
authors.forename: Koichi
authors.initials: K
authors.lastname: Takaguchi
authors.forename: Akio
authors.initials: A
authors.lastname: Moriya
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Miyatake
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Okamoto
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Yabushita
authors.forename: Akinobu
authors.initials: A
authors.lastname: Takaki
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Yamamoto
mesh_terms: D000367:Age Factors; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D019259:Lamivudine / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology / Q000517:prevention & control; D008113:Liver Neoplasms / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; C413685:entecavir; D006147:Guanine